First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2023-07-20
- Target Recruit Count
- 30
- Registration Number
- NCT04882917
- Locations
- ๐บ๐ธ
MD Anderson Center, Houston, Texas, United States
๐บ๐ธNEXT Oncology, San Antonio, Texas, United States
๐จ๐ฆPrincess Margaret Cancer Centre, Toronto, Ontario, Canada
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2023-08-15
- Target Recruit Count
- 76
- Registration Number
- NCT04768296
- Locations
- ๐บ๐ธ
National Cancer Institute, Bethesda, Maryland, United States
๐บ๐ธFirstHealth of the Carolinas, Inc., Pinehurst, North Carolina, United States
๐บ๐ธSumma Health, Akron, Ohio, United States
The MS-LINKโข Outcomes Study
- Conditions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-08-22
- Target Recruit Count
- 2182
- Registration Number
- NCT04735406
- Locations
- ๐บ๐ธ
The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
๐บ๐ธAlabama Neurology Associates, Birmingham, Alabama, United States
๐บ๐ธAtlanta Neuroscience Institute, Atlanta, Georgia, United States
M1231 in Participants With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2023-07-07
- Target Recruit Count
- 23
- Registration Number
- NCT04695847
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center - Clinical Cancer Prevention, Houston, Texas, United States
๐จ๐ฆPrincess Margaret Cancer Centre, Toronto, Canada
๐บ๐ธNEXT Oncology, San Antonio, Texas, United States
Study of M4344 in Combination With Niraparib
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 25
- Registration Number
- NCT04551950
- Locations
- ๐บ๐ธ
Stanford Health Care Hospital & Clinics, Stanford, California, United States
๐ช๐ธHospital Clinic i Provincial de Barcelona - Servicio de Oncologia, Barcelona, Spain
๐ฏ๐ตOsaka International Cancer Institute, Osaka-shi, Japan
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2022-12-22
- Target Recruit Count
- 3
- Registration Number
- NCT04515394
- Locations
- ๐บ๐ธ
University of California, Los Angeles (UCLA), Santa Monica, California, United States
๐บ๐ธAllegheny-Singer Research Institute, Pittsburgh, Pennsylvania, United States
๐บ๐ธCancer Center of Kansas, Wichita, Kansas, United States
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 11
- Registration Number
- NCT04489940
- Locations
- ๐ง๐ช
UZ Leuven, Leuven, Belgium
๐บ๐ธMedical Oncology Hematology Consultants, PA, Helen F. Graham Cancer Center, Suite 3400, Newark, Delaware, United States
๐บ๐ธMayo Clinic-Jacksonville, Jacksonville, Florida, United States
First in Human Study of M6223
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2023-12-08
- Target Recruit Count
- 58
- Registration Number
- NCT04457778
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
๐บ๐ธNext Oncology, San Antonio, Texas, United States
๐จ๐ฆPrincess Margaret Cancer Centre, Toronto, Canada
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 730
- Registration Number
- NCT04459715
- Locations
- ๐บ๐ธ
Inventa Center for Cancer Research At Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ฆMedical center of Yuriy Spizhenko, Soborna Vulytsia, Kyiv, Ukraine